
Few medicines have left as clear a mark on drug regulation as thalidomide. Its use as a sedative in the late 1950s and early 1960s caused severe birth defects in thousands of children, exposed weaknesses in medicines assessment, and accelerated major changes on both sides of the Atlantic.
The consequences were not identical. In the USA, thalidomide helped turn an existing reform effort into the Kefauver-Harris Drug Amendments of 1962. In Europe, the disaster supplied much of the impetus for the first common pharmaceutical legislation of the European Economic Community in 1965.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze